SG11201704155UA - Anti-mutated kras t cell receptors - Google Patents

Anti-mutated kras t cell receptors

Info

Publication number
SG11201704155UA
SG11201704155UA SG11201704155UA SG11201704155UA SG11201704155UA SG 11201704155U A SG11201704155U A SG 11201704155UA SG 11201704155U A SG11201704155U A SG 11201704155UA SG 11201704155U A SG11201704155U A SG 11201704155UA SG 11201704155U A SG11201704155U A SG 11201704155UA
Authority
SG
Singapore
Prior art keywords
cell receptors
mutated kras
kras
mutated
receptors
Prior art date
Application number
SG11201704155UA
Other languages
English (en)
Inventor
Qiong J Wang
Zhiya Yu
James C Yang
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of SG11201704155UA publication Critical patent/SG11201704155UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
SG11201704155UA 2014-11-26 2015-11-24 Anti-mutated kras t cell receptors SG11201704155UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462084654P 2014-11-26 2014-11-26
US201562171321P 2015-06-05 2015-06-05
PCT/US2015/062269 WO2016085904A1 (en) 2014-11-26 2015-11-24 Anti-mutated kras t cell receptors

Publications (1)

Publication Number Publication Date
SG11201704155UA true SG11201704155UA (en) 2017-06-29

Family

ID=54838442

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201704155UA SG11201704155UA (en) 2014-11-26 2015-11-24 Anti-mutated kras t cell receptors
SG10201913978RA SG10201913978RA (en) 2014-11-26 2015-11-24 Anti-mutated kras t cell receptors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201913978RA SG10201913978RA (en) 2014-11-26 2015-11-24 Anti-mutated kras t cell receptors

Country Status (17)

Country Link
US (3) US11207394B2 (enrdf_load_stackoverflow)
EP (3) EP3223850B1 (enrdf_load_stackoverflow)
JP (2) JP6863893B2 (enrdf_load_stackoverflow)
KR (1) KR102622784B1 (enrdf_load_stackoverflow)
CN (3) CN118994363A (enrdf_load_stackoverflow)
AU (3) AU2015353720B2 (enrdf_load_stackoverflow)
CA (1) CA2968399A1 (enrdf_load_stackoverflow)
ES (2) ES2965689T3 (enrdf_load_stackoverflow)
HU (1) HUE065689T2 (enrdf_load_stackoverflow)
IL (1) IL252258B (enrdf_load_stackoverflow)
MX (1) MX384919B (enrdf_load_stackoverflow)
PL (1) PL3223850T3 (enrdf_load_stackoverflow)
PT (1) PT3223850T (enrdf_load_stackoverflow)
SA (1) SA517381608B1 (enrdf_load_stackoverflow)
SG (2) SG11201704155UA (enrdf_load_stackoverflow)
SI (1) SI3223850T1 (enrdf_load_stackoverflow)
WO (1) WO2016085904A1 (enrdf_load_stackoverflow)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015353720B2 (en) * 2014-11-26 2020-02-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated KRAS T cell receptors
WO2017048593A1 (en) * 2015-09-15 2017-03-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing hla-cw8 restricted mutated kras
DK3494133T3 (da) * 2016-08-02 2022-09-19 Us Health Anti-kras-g12d-t-cellereceptorer
WO2018069871A2 (en) * 2016-10-13 2018-04-19 Sorrento Therapeutics, Inc. Anti-kras binding proteins
CN108395479B (zh) * 2017-02-06 2021-07-16 高军 一种有关kras基因突变的t细胞受体
KR20200003390A (ko) 2017-05-08 2020-01-09 그릿스톤 온콜로지, 인코포레이티드 알파바이러스 신생항원 벡터
CN110662760A (zh) 2017-05-12 2020-01-07 奥古斯塔大学研究所公司 人甲胎蛋白特异性t细胞受体及其用途
WO2018213467A1 (en) 2017-05-16 2018-11-22 The Johns Hopkins University Manabodies and methods of using
EA202090652A1 (ru) 2017-09-20 2020-08-21 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез T-клеточные рецепторы, рестриктированные по антигену лейкоцитов человека класса ii, против мутантного ras
EP3688142B1 (en) * 2017-09-29 2025-04-09 The United States of America, as represented by the Secretary, Department of Health and Human Services Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
JP2020535832A (ja) 2017-10-05 2020-12-10 アメリカ合衆国 マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法
CN119162251A (zh) * 2017-12-04 2024-12-20 美国卫生和人力服务部 针对突变的ras的hla i类限制性t细胞受体
CN110016074B (zh) * 2018-01-08 2021-03-30 中国科学院广州生物医药与健康研究院 Mage-a3人源化t细胞受体
WO2019246286A1 (en) 2018-06-19 2019-12-26 Neon Therapeutics, Inc. Neoantigens and uses thereof
JP2021533777A (ja) 2018-08-16 2021-12-09 ビオンテック ユーエス インコーポレイテッド Ｔ細胞受容体構築物およびその使用
WO2020154275A1 (en) * 2019-01-22 2020-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted t cell receptors against ras with g12r mutation
WO2020154617A1 (en) * 2019-01-25 2020-07-30 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting mutant ras
EP3927727A1 (en) * 2019-02-20 2021-12-29 Fred Hutchinson Cancer Research Center Binding proteins specific for ras neoantigens and uses thereof
US20220175899A1 (en) * 2019-04-11 2022-06-09 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer
WO2020237368A1 (en) * 2019-05-27 2020-12-03 Provincial Health Services Authority Immunotherapy constructs targeting kras antigens
AU2020282369A1 (en) 2019-05-30 2022-01-20 Seattle Project Corp. Modified adenoviruses
US20220306688A1 (en) * 2019-06-07 2022-09-29 Emory University KRAS G12V Mutant Binds to JAK1, Inhibitors, Pharmaceutical Compositions, and Methods Related Thereto
CN112110995A (zh) * 2019-06-19 2020-12-22 上海交通大学医学院 肿瘤新抗原多肽及其用途
CN112646024B (zh) * 2019-10-10 2023-03-24 香雪生命科学技术（广东）有限公司 一种识别kras突变的t细胞受体及其编码序列
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
WO2021087840A1 (zh) * 2019-11-07 2021-05-14 武汉华大吉诺因生物科技有限公司 肿瘤免疫治疗多肽及其应用
IL292535A (en) * 2019-11-15 2022-06-01 Gritstone Bio Inc Antigen-binding proteins targeting shared neoantigens
US20230080742A1 (en) * 2020-02-12 2023-03-16 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Hla class i-restricted t cell receptors against ras with g12d mutation
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of use thereof
CN113684258B (zh) * 2020-05-18 2024-08-20 上海赛比曼生物科技有限公司 用于检测鼠源tcr转基因拷贝数的试剂盒及方法
US20230181714A1 (en) * 2020-05-27 2023-06-15 Vanderbilt University Human monoclonal antibodies to venezuelan equine encephalitis virus and uses therefor
KR20230046294A (ko) * 2020-07-16 2023-04-05 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 G12v 돌연변이를 갖는 ras에 대한 hla 클래스 ii-제한된 drb t 세포 수용체
CA3187258A1 (en) 2020-08-06 2022-02-10 Karin Jooss Multiepitope vaccine cassettes
CN112300269B (zh) * 2020-09-29 2022-12-09 中国科学院微生物研究所 Kras突变特异性t细胞受体筛选及抗肿瘤用途
KR20230084524A (ko) * 2020-10-02 2023-06-13 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 G13d 돌연변이를 갖는 ras에 대한 hla 클래스 ii-제한된 dq t 세포 수용체
JP2024507929A (ja) 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
EP4308143A4 (en) * 2021-03-19 2025-06-04 Cue Biopharma, Inc. T-cell modulatory polypeptides and methods of use thereof
CN116063511B (zh) * 2021-09-30 2023-10-03 北京可瑞生物科技有限公司 抗原结合蛋白及其应用
KR102818249B1 (ko) * 2021-11-11 2025-06-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물을 이용한 항원 특이적 t 세포 유도방법
KR102753583B1 (ko) * 2021-11-11 2025-01-10 의료법인 명지의료재단 Kras 특이적 활성화 t 세포 유도용 항원 조성물
US20250101078A1 (en) 2022-01-21 2025-03-27 T-Knife Gmbh Antigen recognizing construct that binds specific peptide with determinable affinity and t cell receptor having antigenic specificity for kras as well as corresponding nucleic acid sequence, vector, host cell, pharmaceutical composition and kit
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
CN114591443A (zh) * 2022-03-07 2022-06-07 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种基于scTv的嵌合受体CSR及其应用
CN114920824B (zh) * 2022-05-27 2023-12-05 重庆医科大学 Tcr或其抗原结合片段及其应用
CN114835800B (zh) * 2022-05-27 2023-10-13 重庆医科大学 Tcr或其抗原结合片段及其应用
EP4584298A1 (en) * 2022-09-08 2025-07-16 The Regents Of The University Of California Binding agent recognition of drug-peptide conjugates
WO2024147556A1 (ko) * 2023-01-05 2024-07-11 의료법인 명지의료재단 K-ras 돌연변이 다중 항원결정기 폴리펩타이드를 유효성분으로 포함하는 항암 백신용 조성물
IL322077A (en) * 2023-01-13 2025-09-01 Corregene Biotechnology Co Ltd Antigen-binding protein and its use
CN118812698A (zh) * 2023-04-19 2024-10-22 香雪生命科学技术（广东）有限公司 一种识别kras突变的高亲和力t细胞受体及其应用
CN118909132A (zh) * 2023-05-06 2024-11-08 北京鼎成肽源生物技术有限公司 靶向kras g12v突变的tcr分子和细胞及其应用
WO2025006196A1 (en) 2023-06-28 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting ras with g12d, g12r, or g12v mutation
CN116574748B (zh) * 2023-07-10 2023-09-12 昆明医科大学 一种用于靶向KRAS高频突变肿瘤的嵌合型nTCR-T构建方法
CN117143823B (zh) * 2023-09-11 2024-07-16 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种基于tcr单链可变区的靶向ras(g12v)的嵌合抗原受体记忆nk细胞的研制及其应用
WO2025056681A1 (en) * 2023-09-15 2025-03-20 Medigene Immunotherapies Gmbh T-CELL RECEPTOR AGAINST mKRAS7-16 G12V AND G12C
WO2025056656A1 (en) * 2023-09-15 2025-03-20 Medigene Immunotherapies Gmbh T-CELL RECEPTOR VARIANT AGAINST mKRAS7-16 G12V

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709002B1 (en) * 1996-04-19 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Mutated ras peptides for generation of CD8+Cytotoxic T lymphocytes
GB2328689A (en) 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
NO315238B1 (no) 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
ES2602145T3 (es) 2002-09-06 2017-02-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inmunoterapia con linfocitos específicos de antígeno seleccionados in vitro después de quimioterapia supresora de linfocitos no mieloablativa
JP5079697B2 (ja) * 2005-08-05 2012-11-21 ヘルムホルツ ツェントラム ミュンヘン ドイチェス フォーシュングスツェントラム フュール ゲズントハイト ウント ウンヴェルト ゲーエムベーハー 抗原特異的ｔ細胞の生成方法
CA2651174A1 (en) * 2006-05-03 2007-11-15 Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
US8216565B2 (en) * 2007-01-12 2012-07-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services GP100-specific T cell receptors and related materials and methods of use
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
AU2010295689B2 (en) 2009-09-17 2014-02-13 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
CN104131034B (zh) * 2014-06-19 2017-04-05 中山大学 一种嵌合载体及其制备方法和应用
AU2015353720B2 (en) * 2014-11-26 2020-02-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated KRAS T cell receptors
CN105802909B (zh) * 2014-12-31 2021-01-01 中国医学科学院基础医学研究所 具有her2特异性tcr的t细胞制备物及其用途
CN108395479B (zh) * 2017-02-06 2021-07-16 高军 一种有关kras基因突变的t细胞受体
CN113621070A (zh) * 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用

Also Published As

Publication number Publication date
AU2015353720A1 (en) 2017-06-08
PL3223850T3 (pl) 2020-08-24
HUE065689T2 (hu) 2024-06-28
EP3666288A1 (en) 2020-06-17
PT3223850T (pt) 2020-04-13
IL252258A0 (en) 2017-07-31
US11207394B2 (en) 2021-12-28
JP6863893B2 (ja) 2021-04-21
ES2965689T3 (es) 2024-04-16
CN113956349A (zh) 2022-01-21
SI3223850T1 (sl) 2020-09-30
HK1243642A1 (en) 2018-07-20
JP2021104044A (ja) 2021-07-26
JP2017536825A (ja) 2017-12-14
EP4286407A2 (en) 2023-12-06
AU2020203465B2 (en) 2022-11-17
CN107223134B (zh) 2021-11-16
CA2968399A1 (en) 2016-06-02
ES2784261T3 (es) 2020-09-23
SG10201913978RA (en) 2020-03-30
EP3223850B1 (en) 2020-01-08
AU2023200614A1 (en) 2023-03-09
AU2020203465A1 (en) 2020-06-18
EP4286407A3 (en) 2024-03-06
MX2017006865A (es) 2018-01-11
NZ732045A (en) 2024-04-26
US20220088164A1 (en) 2022-03-24
US20170304421A1 (en) 2017-10-26
EP3223850A1 (en) 2017-10-04
IL252258B (en) 2021-12-01
SA517381608B1 (ar) 2021-03-11
JP7297807B2 (ja) 2023-06-26
CN107223134A (zh) 2017-09-29
CN118994363A (zh) 2024-11-22
KR102622784B1 (ko) 2024-01-09
EP3666288B1 (en) 2023-09-27
WO2016085904A1 (en) 2016-06-02
US12312391B2 (en) 2025-05-27
KR20170099905A (ko) 2017-09-01
AU2015353720B2 (en) 2020-02-27
CN113956349B (zh) 2024-09-06
US20250263462A1 (en) 2025-08-21
MX384919B (es) 2025-03-14

Similar Documents

Publication Publication Date Title
IL274903A (en) cell
IL252258B (en) K-R-EST anti-mutation cell receptors
ZA201806862B (en) T cell receptors
ZA201806866B (en) T cell receptors
IL262144A (en) t cell receptors
ZA201806865B (en) T cell receptors
IL264425B1 (en) t cell receptors against kras-g20
ZA201701823B (en) T cell receptors
GB201522592D0 (en) T cell receptors
PL3433270T3 (pl) Receptory limfocytów t
HUE042287T2 (hu) Lítium-kén cella
HK40065450B (en) Anti-mutated kras t cell receptors
GB201518991D0 (en) T cell receptors
HK1238270A1 (zh) T细胞受体
GB201410934D0 (en) T cell